Anacor and MMV Expand Partnership to alter Proof-of Concept Study with ... Genetic Engineering tidings AN2728 is a topical anti-inflammatory candidate that has completed Phase II studies for the treatment of psoriasis , and is also in Phase 2 development for the attention of atopic dermatitis. In June Anacor reported affirmative preliminary results from type A ... Anacor Pharmaceuticals and Medicines for Malaria project Extend Development ... MarketWatch (press release) all ii news articles » Link To Article
No comments:
Post a Comment